Due: September 30, 2026 The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials Read More
Due: September 30, 2026 The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must Read More
Due: September 28, 2026 The purpose of this announcement is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system Read More
Due: September 28, 2026 The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Idea Development Award (IDA) supports the development of high-impact ideas that advance the understanding of kidney cancer and ultimately lead to Read More
Due: September 25, 2026 Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). The program will fund P50 SPORE Read More
Due: September 24, 2026 The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Care Award (TrCA) supports clinical research or clinical trials evaluating interventions, innovations, and solutions in critical areas for dementia care for Read More
Due: September 24, 2026 The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Diagnosis Award (TrDA) supports non-incremental, solutions-oriented research that reduces or overcomes important barriers to obtaining a diagnosis, meaningful disease monitoring and Read More
Due: September 24, 2026 The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Research Award (TrRA) supports non-incremental, robust, well-designed research that drives transformative advancements in reducing risk and preventing the development of Alzheimer’s Read More
Due: September 14, 2026 ASPR IBMSC is seeking to establish vendor managed inventory (VMI) capabilities for active pharmaceutical ingredients (APIs) used in medical countermeasure finished dose form (FDF) drug products. This scope includes providing a Read More
Due: September 8, 2026 ASPR IBMSC is seeking to expand the domestic manufacturing capacity of nitrile gloves. This capacity expansion is essential to ensure sufficient nitrile gloves availability in response to surge demand during future Read More
NTA is operated by the 501c(3) non-profit Advanced Technology International (ATI). National Technology Alliance (NTA) © 2026 - All rights reserved.